TSMHT
CRMD icon

Thurston Springer Miller Herd & Titak’s CorMedix CRMD Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,500
Closed -$18.5K – 705
2025
Q2 		$18.5K Hold
1,500
– – ﹤0.01% 970
2025
Q1 		$9.24K Hold
1,500
– – ﹤0.01% 1146
2024
Q4 		$12.2K Buy
+1,500
New +$15K ﹤0.01% 842

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's CRMD Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 1,500 shares — an estimated $18.5K sold.

Thurston Springer Miller Herd & Titak first reported a position in CRMD in Q4 2024 and held it in 3 quarters. The position peaked at $18.5K in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 1,500 CorMedix shares in Q3 2025, an estimated $18.5K.
  • Thurston Springer Miller Herd & Titak first reported a position in CorMedix in Q4 2024 and held it in 3 quarters.
  • Thurston Springer Miller Herd & Titak's CorMedix position peaked at $18.5K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.